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Small-molecule drugs that increase 26S
proteasome have many potential
therapeutic applications, including in
neurodegenerative diseases. Here,
Leestemaker et al. describe the
identification of more than ten small-
molecule compounds that increase
proteasome activity and increase the
clearance of model substrates.
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Drugs that increase 26S proteasome activity have
potential therapeutic applications in the treatment
of neurodegenerative diseases. A chemical genetics
screen of over 2,750 compounds using a proteasome
activity probe as a readout in a high-throughput live-
cell fluorescence-activated cell sorting-based assay
revealed more than ten compounds that increase
proteasome activity, with the p38 MAPK inhibitor
PD169316 being one of the most potent ones. Ge-
netic and chemical inhibition of either p38 MAPK,
its upstream regulators, ASK1 andMKK6, and down-
stream target, MK2, enhance proteasome activity.
Chemical activation of the 26S proteasome in-
creases PROTAC-mediated and ubiquitin-depen-
dent protein degradation and decreases the levels
of both overexpressed and endogenous a-synuclein,
without affecting the overall protein turnover. In addi-
tion, survival of cells overexpressing toxic a-synu-
clein assemblies is increased in the presence of
p38 MAPK inhibitors. These findings highlight the
potential of activation of 26S proteasome activity
and that this can be achieved throughmultiple mech-
anisms by distinct molecules.
INTRODUCTION
The ubiquitin-proteasome system (UPS) is the main cellular
machinery responsible for the degradation of intracellular pro-
teins in eukaryotic cells and key to the regulation of cellular pro-
cesses including proliferation, cell-cycle control, transcriptional
regulation, and stress response (Glickman and Ciechanover,
2002). Uponmodification with specific ubiquitin chains that func-
tion as a degradation signal, proteins are recognized and subse-Cell Chemquently degraded by the 26S proteasome. The 26S proteasome
is composed of a 20S catalytic core particle (CP) capped on one
or both sides by a 19S regulatory particle (RP). The 20S CP con-
sists of four stacked rings that contain seven subunits each and
has an overall architecture of a(1–7)b(1–7)b(1–7)a(1–7). The two
outer a rings provide binding sites for the 19S RPs and form a
gated channel that controls access to the catalytic chamber.
The catalytic activity resides within the two inner b rings and is
provided by three constitutive subunits, termed b1, b2, and b5,
that display caspase-like, tryptic-like, and chymotryptic-like ac-
tivity, respectively. The 19S RP is responsible for the recognition
and unfolding of protein substrates and, upon ATP binding,
opens the gated channel of the 20S CP, allowing translocation
of the substrates into the 20S CP (Glickman and Ciechanover,
2002). In lymphoid tissues, or after induction with the proinflam-
matory cytokines, interferon-g or tumor necrosis factor alpha,
the constitutive b subunits can be replaced by their immunopro-
teasome counterparts, termed b1i, b2i, and b5i, to form the im-
munoproteasome ormixed-type hybrid proteasomes (Dahlmann
et al., 2000; Pelletier et al., 2010). In addition, two cell type-spe-
cific proteasome subtypes with differing subunit composition
have been described, the thymoproteasome and the spermato-
proteasome (Kniepert and Groettrup, 2014).
As the 26S proteasome is involved in many important regula-
tory processes, it is an attractive target for therapeutic interven-
tion. The potential of proteasome-modulating drugs is illustrated
by the success of the proteasome inhibitor bortezomib (Hide-
shima et al., 2001), which is used for the treatment of multiple
myeloma and mantle cell lymphoma. Compounds that increase
proteasome activity may also be of significant therapeutic value.
Proteasome function becomes gradually impaired during aging
and many age-related neurodegenerative disorders, including
Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyo-
trophic lateral sclerosis (ALS) are characterized by the presence
of toxic intracellular protein aggregates that correlate with
a reduction in proteasome activity (Kristiansen et al., 2007;
Rubinsztein, 2006). In turn, oligomeric aggregates of proteins
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to bind to proteasomes in vitro and in vivo, thereby inhibiting
its activity (Dantuma and Bott, 2014; Kristiansen et al., 2007;
Myeku et al., 2016; Snyder et al., 2003). Moreover, inhibition
of the proteasome results in the induction of a-synuclein aggre-
gation, characteristic of PD, and neurodegeneration in a mouse
model (Ebrahimi-Fakhari et al., 2011). This suggests a central
role for the proteasome in a vicious cycle in neurodegenera-
tive disease pathogenesis. Enhancing UPS activity, by either
increasing the pool of free ubiquitin (Lee et al., 2009) or overex-
pressing specific ubiquitin ligases (Al-Ramahi et al., 2006; Tsai
et al., 2003), can reduce toxicity induced by protein aggregates.
Also enhancing proteasome activity by small-molecule com-
pounds has been postulated to be of therapeutic value in the
treatment of neurodegenerative diseases (Dantuma and Bott,
2014; Lee et al., 2010a). But, although a subset of proteasome
activity-enhancing compounds has been reported, only very
few have been shown to activate proteasomes in vivo. Sulfo-
raphane increases proteasome levels in vivo through induction
of the transcription factor Nrf2 (Liu et al., 2014). IU1 enhances
proteasomal degradation by inhibiting USP14, a proteasome-
associated deubiquitinating enzyme (Lee et al., 2010a). Roli-
pram enhances 26S proteasome activity and reduces levels of
aggregated tau in vivo by activating protein kinase A (PKA)
(Myeku et al., 2016).
The lack of suitable screening assays hinders the identification
of small-molecule compounds that enhance proteasome activ-
ity. Current assays can only be used in vitro or monitor degrada-
tion by introducing tagged and often overexpressed model sub-
strates. Such limitations can be overcome by the use of chemical
probes, which allows for identification of novel proteasome ac-
tivity-modulating compounds in primary cells, established cell
lines, or in tissues. In this study we deploy such an activity-based
probe (Berkers et al., 2007; de Jong et al., 2012) to identify new
drug-like small molecules that can increase 26S proteasome
activity in cells. Using this approach, we identify 11 novel com-
pounds that enhance proteasome activity up to 4-fold in cells.
In addition, we identify an important novel role for chemical
and genetic inhibitors of p38a MAPK in activating the protea-
some and enhancing degradation of specific proteins, including
a-synuclein.
RESULTS
Identification of Novel Small-Molecule Proteasome
Activators
To identify novel small molecules that are able to activate protea-
some in intact cells, we used the cell-permeable fluorescent pro-Figure 1. Identification of Small-Molecule Proteasome Activators Usin
(A and D) In-gel fluorescence scan showing representative proteasome activity pr
K+, or ATP-gS or (D) MelJuSo cells after a 16 hr incubation with 5 mM compound
(B) Rate of suc-LLVY-AMC conversion in MelJuSo cell lysates treated with MG1
independent experiments.
(C) Structures of small-molecule compounds that increase proteasome activity.
(E) Intracellular fluorescence intensities inMelJuSo cells after a 16 hr incubation w
or reduced probe 1 (termed reactive probe and control probe, respectively). All s
cells. Error bars represent SD of three independent experiments.
(F) The rate of suc-LLVY-AMC conversion in MelJuSo cells treated with 5 mM of th
cells and epoxomicin-treated cells (Epox) were set to 1 and 0, respectively. Error b
not significant, *p % 0.05, **p % 0.01, ***p % 0.001, and ****p % 0.0001. See alsteasome activity reporter Me4BodipyFLAhx3L3VS (probe 1;
Figure S1A). Probe 1 covalently binds to catalytically active sub-
units of the proteasome in living cells in an activity-dependent
manner. Hence, treatment of cells with negative or positive mod-
ulators of proteasome activity followed by probe treatment re-
sults in reduced or increased intracellular fluorescence, respec-
tively, which can be measured by flow cytometry or SDS-PAGE
followed by fluorescence scanning (Berkers et al., 2007; de Jong
et al., 2012).
To further characterize probe 1, we first performed time-
dependent experiments by flow cytometry (Figure S1B) using
both probe 1 and its inactive counterpart, in which the vinyl sul-
fone moiety is reduced by hydrogenation (reduced probe 1; Fig-
ure S1A). Whereas the intracellular fluorescence using probe 1
increases linearly over time, the (background) fluorescence
observed using the reduced probe stays constant over time,
indicating that probe 1 can be used to assay the rate of reac-
tion of the proteasome in cells. Next, we determined whether
probe 1 accesses the proteasome via the gated channel, as
protein substrates would, or whether it can diffuse into the
proteasome without entering through the gate. To this end,
the gated channel of the proteasome was chemically opened
in MelJuSo (human melanoma) cell lysates by adding non-hy-
drolyzable ATP-gS (Li and Demartino, 2009) or closed by adding
ADP and K+ (Köhler et al., 2001; Peth et al., 2009) (Figure S1C).
Subsequently, proteasome activity was profiled by separating
subunits using SDS-PAGE. As can be seen in Figure 1A, ADP
and K+ treatment strongly reduced probe binding compared
with untreated control, comparable with treatment with protea-
some inhibitor MG132. Interestingly, ATP-gS did not increase
proteasome activity, as assayed by probe 1 binding or by
measuring the conversion of the fluorogenic proteasome
substrate suc-LLVY-AMC (suc-LeuLeuValTyr-aminomethylcou-
marin) (Figure 1B), indicating that in our hands the gated chan-
nel is already fully opened in MelJuSo cell lysates. As expected,
opening or closing of the gated channel following probe addition
did not change probe binding (Figure S1D). These data indicate
that (like proteinaceous substrates) proteasome probes only
enter the 20S particle if the gated channel is in an open confor-
mation. Thus, although probe binding does not fully mimic the
normal ubiquitin-mediated proteasomal protein degradation
route, proteasome probes are suitable tools to screen for pro-
teasome activation.
Next, we took a forward chemical genetics approach to
identify proteasome-activating compounds and used probe 1
to screen both the Library of Pharmacologically Active Com-
pounds and Johns Hopkins Clinical Compound Library in ag a Proteasome Activity Probe
ofiles in (A) MelJuSo cell lysates treated with MG132 or (combinations of) ADP,
or 750 nM MG132. Bars represent the quantified probe signal.
32 or (combinations of) ADP, K+, or ATP-g. Error bars represent SD of three
ith 5 mMof the indicated compounds, followed by incubation with either probe 1
ignals were normalized to intensities obtained in DMSO-treated control (CTR)
e indicated compounds. The conversion rates in DMSO-treated control (CTR)
ars represent SD of three independent experiments. Statistical significance: ns,
o Figures S1 and S2.
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high-throughput flow cytometry-based assay (Figure S1E).
Validation of the primary screening results by both flow cytome-
try and gel-based proteasome activity assays yielded 11 com-
pounds that increased proteasome activity from 2- to 4-fold at
concentrations of 5 mM (Figures 1C, 1D, and 1E), without any
apparent toxicity as determined by a cell-titer blue cell viability
assay (Figure S1F). In addition, we did not observe any changes
in the overall levels of ubiquitinated proteins (Figure S1G). SDS-
PAGE readouts of proteasome activity showed that all the iden-
tified compounds enhanced proteasome activity by increasing
the activity of both the b1/5 and the b2 subunits (Figure 1D).
Three other compounds activated the proteasome to a lesser
extent (Figures S1H and S1I). The effects of all the compounds
on proteasome activity could be confirmed in a panel of human
cell lines, including HeLa, MCF-7, HEK293T, and THP-1 cells
(Figure S2). When we tested the effect of IU1 under the same
conditions, we observed little effect on the proteasome activity
(Figures 1D, 1E, and S2A). However, when we used higher con-
centrations of IU1 (up to 25 mM), we did observe an increase in
proteasome activity (Figures S2B and S2C). One of the com-
pounds identified as a proteasome activator is Verapamil, a
known inhibitor of drug efflux pump proteins, such as P-glyco-
protein (Perrotton et al., 2007), suggesting that this could be a
false-positive hit. In the original screen, however, Verapamil
was present as a racemic mixture. When we tested the R- and
S-enantiomers separately we observed that the R-enantiomer
of Verapamil activated proteasome activity more strongly than
the S-enantiomer (Figure S1J). Interestingly, S-Verapamil is a
far more potent inhibitor of P-glycoprotein activity than R-Verap-
amil. To exclude the possibility that the observed increase in pro-
teasome labeling induced by any of the other compounds was
due to increased uptake or retention of the probe, we repeated
the fluorescence-activated cell sorting assay with reduced
probe 1. Using this control probe, no increase in intracellular
fluorescence was observed with any of the compounds, indi-
cating that the cellular uptake and retention of probe 1 were
unaffected by all compounds (Figure 1E). Furthermore, all
compounds increased the intracellular degradation rate of suc-
LLVY-AMC in an orthogonal proteasome activity assay up to
2.5-fold (Figure 1F). The overall levels of proteasome activation
are lower when measured through suc-LLVY-AMC degradation
compared with probe 1 binding. Likely, the high background
levels that are measured when using fluorogenic substrates in
cells make assays using probe 1 more sensitive than small fluo-
rogenic substrate-based assays. Together, these data show that
the observed increase in probe labeling can be attributed to an
increase in proteasome activity, and verify that all 11 compounds
are able to activate proteasomes and increase substrate turn-
over in intact cells.
Inhibition of p38a MAPK and Its Downstream Target
MK2 Both Activate the Proteasome
One of the identified compounds, PD163916, is an established
active-site inhibitor (type 1 inhibitor) of p38 MAPK. p38 MAPK-
dependent phosphorylation has previously been shown to
reduce proteasome activity in response to osmotic stress (Lee
et al., 2010b). Moreover, the presence of activated p38 has
been observed in neurodegenerative diseases, including ALS
(Bendotti et al., 2004; Tortarolo et al., 2003) and AD (Atzori728 Cell Chemical Biology 24, 725–736, June 22, 2017et al., 2001; Zhu et al., 2000). Hence, we next focused on p38
MAPK-inhibiting compounds. A panel of p38 MAPK inhibitors
was tested for their ability to increase intracellular proteasome
activity in MelJuSo cells, including SB202190 and SB203580
(both PD169316 analogs and fully ATP-competitive type 1 inhib-
itors) and the structurally different p38a inhibitor skepinone-L,
which is highly selective due to induced glycine-flip at the hinge
region of the kinase (Koeberle et al., 2012) (Figure 2A). As ex-
pected, all inhibitors activated the proteasome in a dose-depen-
dent manner as assayed using the probe-based flow cytometry
assay (Figure 2B). In addition, all p38 MAPK inhibitors increased
the activity of both the b1/5 and b2 subunits, without affecting
subunit abundance (Figure 2C), cell viability (Figure S3A), or
the overall levels of ubiquitinated proteins (Figure S3B). All com-
pounds were also able to increase the intracellular turnover of
suc-LLVY-AMC (Figure 2D).
Four p38 MAPK isoforms have been described (a, b, g, and d),
with p38a MAPK being the major isoform (Borst et al., 2013),
which could be confirmed in MelJuSo cells by analyzing
p38 mRNA levels (Figure S3C). To investigate which isoforms
mediate the observed proteasome-activating effect, all p38
MAPK isoforms were individually depleted from MelJuSo
cells using small interfering RNA (siRNA), followed by incuba-
tion with a proteasome activity probe. While siRNA depletion
decreased the levels of all the individual isoforms by at least
80% (Figure S3D), only p38a knockdown resulted in a substan-
tial increase in proteasome activity (Figure 2E). In contrast,
knockdown of p38b only slightly enhanced proteasome activity,
while no effect on proteasome activity was observed upon
depletion of either p38g or p38d isoforms. These data are in
line with the isoform preference of the used p38 inhibitors that
are all slightly preferential for the a versus the b isoform, but do
not inhibit the g and d isoforms (Koeberle et al., 2012). Gel-based
activity assays confirmed that p38a depletion resulted in an
enhanced activity of both b1/5 and b2 subunits, without affecting
the protein levels of b subunits (Figure 2F). Treatment with
PD169316 following the depletion of p38a from MelJuSo cells
did not further increase proteasome activity (Figure 2G), confirm-
ing that the p38 MAPK inhibitors described here activate the
intracellular proteasome pool by directly inhibiting p38 MAPK
and not through an off-target effect.
Finally, we asked which up- and downstream players in the
p38 MAPK pathway were involved in the p38a-dependent acti-
vation of the proteasome. To this end, we performed a siRNA
screen in MelJuSo cells against kinases that have previously
been implicated in the MAPK signaling pathways. Of these ki-
nases, only knock down of the upstream p38 regulators ASK1
(apoptosis signal-regulating kinase 1) and MKK6 (MAP kinase
kinase 6), as well as the p38 MAPK target protein MK2, resulted
in an over 2-fold enhancement of intracellular proteasome activ-
ity as measured by flow cytometry (Figures 3A and S3E). Both
gel-based activity assays and measurements of the intracellular
suc-LLVY-AMC conversion confirmed that ASK1 and MK2
knockdown enhanced the intracellular proteasome activity,
without changing the protein levels of b5 subunits (Figures 3B,
3C, and S3F). No significant increase in suc-LLVY-AMC conver-
sion was observed for cells treated with siRNAs against MKK6








Figure 2. Chemical and Genetic Inhibition of p38 MAPK Increase Intracellular Proteasome Activity
(A) Structures of p38 MAPK active-site inhibitors PD169316, SB202190, SB203580, and p38 MAPK allosteric inhibitor skepinone-L.
(B) Intracellular fluorescence intensities in MelJuSo cells, treated with probe 1 after a 16 hr incubation period with increasing concentrations of the indicated p38
MAPK inhibitors. All signal intensities were normalized to intensities obtained in DMSO-treated control (CTR) cells. Error bars represent SD of three independent
experiments.
(C) In-gel fluorescence scan (top) showing representative proteasome labeling profiles in MelJuSo cells after a 16 hr incubation period with 5 mM of the indicated
compounds or 750 nM MG132. Bars represent the quantified probe signal. Immunoblot analysis of the levels of the indicated proteins (bottom). GADPH levels
were used as a loading control.
(D) The rate of suc-LLVY-AMC conversion in MelJuSo cells treated with 5 mM of the indicated compounds. The conversion rates in DMSO-treated control (CTR)
cells and epoxomicin-treated cells were set to 1 and 0, respectively. Error bars represent SD of three independent experiments. Statistical significance: ns, not
significant, **p % 0.01, ***p % 0.001, and ****p % 0.0001.
(E) Intracellular fluorescence intensities inMelJuSo cells, treatedwith probe 1 after 72 hr transfectionwith siRNAs targeting the indicated proteins or control siRNA
(siCTR). All signal intensities were normalized to intensities obtained in non-transfected (NT) cells. Error bars represent SD of three independent experiments.
(F) In-gel fluorescence scan (top) showing representative proteasome labeling profiles in MelJuSo cells after 72 hr transfection with either control siRNA or siRNA
targeting p38aMAPK. Bars represent the quantified probe signal. Immunoblot analysis of the levels of the indicated proteins (bottom). GADPH levels were used
as a loading control.
(G) Intracellular fluorescence intensities in MelJuSo cells, treated with probe 1 after 72 hr transfection with siRNAs targeting the indicated proteins or control
siRNA (siCTR), followed by a 16 hr incubation with PD169316 or DMSO. All signal intensities were normalized to intensities obtained in NT cells. Error bars
represent SD of three independent experiments.
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Figure 3. Involvement of p38 MAPK Pathway in Proteasome Modulation
(A) Normalized intracellular fluorescence intensities in probe 1-treated MelJuSo cells after 72 hr transfection with siRNAs targeting the indicated proteins in the
p38 MAPK pathway. The color of the box indicates fold activation of siRNA over control siRNA.
(B) Rate of suc-LLVY-AMC conversion in MelJuSo cells after 72 hr transfection with siRNA targeting the indicated proteins. The conversion rates in cells
transfected with control siRNA (siCTR) and epoxomicin-treated cells were set to 1 and 0, respectively. Error bars represent SD of three independent experiments.
Statistical significance: ns, not significant, *p % 0.05, and **p % 0.01.
(C) In-gel fluorescence scan (top) showing representative proteasome labeling profiles in MelJuSo cells after 72 hr transfection with either control siRNA or siRNA
targeting the indicated proteins. Bars represent the quantified probe signal. Immunoblot analysis (bottom) showing the expression levels of the indicated proteins.
GAPDH levels were used as a loading control. See also Figures S3 and S4, Tables S1 and S2.p38 MAPK-Mediated Proteasome Activation and
Inhibition Work through Distinct Mechanisms
To investigate whether p38 MAPK inhibitor-treated cells retain
their increased activity also after cell lysis, HEK293 cells stably
expressing HTBH (histidine tag-TEV cleavage sequence-biotin
tag-histidine tag) tagged Rpn11 (Wang et al., 2007) (a 19S RP
subunit) were treated with PD169316, skepinone-L, or MK2 in-
hibitor III (Anderson et al., 2007) (Figure 4A). Alternatively, p38a
was depleted from these cells using siRNA. Subsequently, pro-
teasomes from these cells were affinity purified (Figures S4A
and S4B) as described previously (Wang et al., 2007), and the
activity of these isolated proteasomes was measured. Both the
probe-based proteasome activity assay and measurement of
suc-LLVY-AMC hydrolysis showed that proteasomes, once acti-730 Cell Chemical Biology 24, 725–736, June 22, 2017vated in cells, retain their enhanced activity, even after mild cell
lysis and purification (Figures 4B and 4C). This suggests that pro-
teasome activation by p38 MAPK inhibition does occur through
direct modulation of proteasome complexes, for example via
post-translationally modification of these complexes.
Previous studies have shown that both overexpressed p38
MAPK and ASK1 phosphorylate the 19S RP, at Thr-273 of the
Rpn2 subunit and on Rpt5, respectively (Lee et al., 2010b; Um
et al., 2010), resulting in proteasome inhibition. Therefore, we
next determined whether changes in the phosphorylation status
of the proteasome could also be responsible for the observed
activation by p38 MAPK inhibition. To this end, we analyzed
changes in the phosphorylation status of cells treated with





Figure 4. PD169316 and MK2 Inhibitor III Activate the Proteasome through Distinct Mechanisms
(A) The structure of MK2 inhibitor III.
(B) In-gel fluorescence scan (top) showing representative proteasome labeling profiles of purified proteasome preparations, obtained from HTBH-Rpn11-
HEK293T cells after a 16 hr incubation period with 5 mM of the indicated compounds or after 72 hr transfection with siRNA targeting p38 MAPKa. Bars represent
the quantified probe signal. Immunoblot analysis (bottom) of the levels of the indicated proteins. GAPDH levels were used as a loading control.
(C) Suc-LLVY-AMC conversion by purified proteasome preparations, obtained from HTBH-Rpn11-HEK293T cells after a 16 hr incubation period with 5 mMof the
indicated proteasome activators or 750 nM MG132 (top). Quantification of substrate turnover (bottom). Error bars represent SD of three independent experi-
ments. Statistical significance: *p % 0.05, **p % 0.01, ***p % 0.001.
(D) Intracellular fluorescence intensities in probe 1-treatedMelJuSo cells after a 16 hr incubation period with the indicated (combinations of) p38MAPK inhibitors.
All signals were normalized to intensities obtained in DMSO-treated control (CTR) cells. Error bars represent SD of three independent experiments.approach. Following treatment of MelJuSo cells with either in-
hibitor or DMSO, the 26S proteasome was enriched by affinity
purification. Both gel-based proteasome activity assays and
measurements of suc-LLVY-AMC conversion confirmed that
these proteasome preparations showed increased activity (Fig-
ures S4C and S4D). After lysC and trypsin digestion, the purified
samples were either subjected to liquid chromatography-
tandem mass spectrometry (LC-MS/MS) directly or further sub-
jected to phosphopeptide enrichment using an automated
Fe(III)-IMAC approach (Abelin et al., 2016) prior to LC-MS/MS
analysis, allowing quantification of phosphorylated proteasomal
peptides. Although many known and yet undescribed phospho-
sites could be detected on these purified proteasomes, no signif-
icant differences were found between non-treated cells and cells
treatedwith inhibitors of the p38MAPKpathway at both total andphosphoprotein levels, including the Rpn2 Thr-273 phospho-
peptide (Tables S1 and S2). These data suggest that, although
the proteasome can be inhibited through direct phosphorylation,
proteasome activation is not necessarily mediated through
direct phosphorylation.
We next investigated whether other known mechanisms were
involved in the enhancement of proteasome activity through the
p38 MAPK pathway inhibition. Increased proteasome subunit
transcription and/or translation are among the most common
mechanisms of proteasome activation. However, no increase
in the mRNA levels of the 20S core subunits PSMB5, PSMB6,
and PSMB7 was observed in p38 MAPK inhibitor-treated cells
compared with control cells, as determined by real-time PCR
(Figure S4E). Moreover, using established 20S subunit ELISA
(Heubner et al., 2011) and immunoblot assays, no increaseCell Chemical Biology 24, 725–736, June 22, 2017 731
was detected in the total amount of 20S proteasome or in the
level of the 19S RPT6 or 20S b5 subunits, respectively (Figures
2C, S4F, and S4G). The assembly of 19S and 20S particles
into 26S proteasome is another mechanism known to increase
proteasome activity. To study whether proteasome assembly
was affected by p38 MAPK inhibition, we treated MelJuSo cells
with PD169316, MK2 inhibitor III, or DMSO, followed by cell lysis.
These cells were subsequently fractionated using size-exclusion
chromatography and the total amount of proteasome in each
fraction was determined by measuring the amounts of subunits
specific to the 19S and 20S proteasome using mass spectrom-
etry (Figure S4H). Quantification values of the different 19S or
20S subunits were averaged and plotted against the fraction
number. We only analyzed those fractions with LC-MS/MS, in
which the proteasome was showing activity, as determined by
the gel-based activity assay, and also measured b5 protein
levels in these fractions (Figure S4I). Treatment with either inhib-
itor did not seem to induce a clear shift in elution profile (Fig-
ure S4H) and the amount of 19S and 20S proteasome in the
fraction containing 26S proteasome (fraction 1) compared with
fractions containing the unassembled particles (fractions 5–6
for the 20S proteasome) did not substantially change. Also the
proteasome activity profiles and the b5 immunoblots show no
changes in the inhibitor-treated cells compared with control
cells. In addition, proteomics analyses of proteasome com-
plexes that were immunoprecipitated through HTBH-tagged
Rpn11 (a 19S subunit) did not show any significant change in
the relative levels of 19S and 20S subunits (Tables S1 and S2).
Together with the observation that activated proteasomes retain
their activity after purification, these results indicate that inhibi-
tion of the p38 pathway likely does not affect proteasome
assembly. In addition, proteomics data indicate that neither
the levels nor the phosphorylation status of the proteasome ac-
tivators PSME1-4 or chaperones PSMG1-3, that co-immunopre-
cipitated with the proteasome, showed any significant change
between treatment conditions (Tables S1 and S2). This suggests
that proteasome activation is not mediated through differential
recruitment of these subunits to the proteasome.
We also asked whether MK2 and p38 MAPK inhibition en-
hances proteasome activity through distinct mechanisms. To
this end, we treated MelJuSo cells with different concentrations
of PD169316 and MK2 inhibitor III alone, or in combination at
concentrations well below the half maximal inhibitory concentra-
tion (IC50) values (Figure S4J), followed by probe 1 labeling and
flow cytometry analysis (Figure 4D). Whereas treatment with
0.25 mM PD169316, or 5 or 10 mM MK2 inhibitor III alone, only
marginally activated intracellular proteasomes, the combination
of both inhibitors at the same sub IC50 concentrations enhanced
the proteasome activity to near maximal capacity (4-fold
activation). Moreover, the concentration of either inhibitor alone
needed to reach a similar extent of proteasome activation was
5- to 10-fold higher, suggesting that PD169316 and MK2 inhib-
itor III operate synergistically in enhancing proteasome activity.
p38MAPK Inhibition Increases the Degradation of Toxic
Protein Assemblies
Finally, we asked whether inhibition of the p38 MAPK pathway
and the subsequent activation of the proteasome represents
a viable therapeutic strategy to clear toxic protein aggregates732 Cell Chemical Biology 24, 725–736, June 22, 2017associated with many neurodegenerative diseases. Therefore,
we first assessed to what extent p38a inhibition can increase
proteasome activity. To this end, we depleted p38a from
MelJuSo cells using siRNA to maximize proteasome activity,
followed by cell lysis. Next, recombinant p38aD176A/F372S, a
constitutively active mutant of p38a (Avitzour et al., 2007), was
added to the lysate in either the presence or absence of
PD169316, after which the turnover of suc-LLVY-AMC was
measured. Whereas addition of PD169316 alone did not affect
the proteasome activity, as expected, supplementation with
recombinant p38aD176A/F372S resulted in an over 4-fold reduction
in proteasome activity (Figure 5A). Importantly, inhibition of
supplemented p38a with PD169316 almost completely restored
suc-LLVY-AMC turnover, resulting in an almost 4-fold enhance-
ment of proteasome activity. These results indicate that p38
MAPK inhibition can strongly increase proteasome activity.
The effect of p38 MAPK inhibition is especially apparent when
basal proteasome activity is low, as has been observed in
various neurodegenerative diseases (Dantuma and Bott, 2014;
Kristiansen et al., 2007; Rubinsztein, 2006), underscoring the
therapeutic promise of this class of compounds.
Next, we monitored the effect of p38 MAPK inhibition on the
degradation of both endogenous and overexpressed model
protein substrates. The turnover of most proteins, including
endogenous estrogen receptor ERa, overexpressed P16, and
overexpressed GFP-Bcl-B, was not affected by treatment with
proteasome activators, suggesting that the bulk of cellular
proteins remain unaltered by proteasome activation. However,
p38 MAPK inhibition did result in reduced cellular levels of HA-
GFP compared with DMSO-treated control cells (Figure 5B).
To examine whether p38 inhibition can also enhance the degra-
dation of ubiquitinated proteins, we used a PROTAC method
(Sakamoto et al., 2001). Recently, the compound dBET1 was
reported to prompt specific degradation of BRD4 by increasing
BRD4 polyubiquitination by the E3 ligase cereblon (CRBN)
(Winter et al., 2015). As can be seen in Figure 5C, preincubation
with PD169316 enhanced the dBET1-induced degradation of
BRD4, without altering the protein levels of CRBN. These results
indicate that p38 inhibition can increase the ubiquitin-dependent
degradation of proteins.
We also examined whether p38 MAPK inhibition can increase
the clearance of toxic protein assemblies by measuring the
degradation of overexpressed a-synuclein in a bimolecular fluo-
rescence complementation (BiFC) assay (Outeiro et al., 2008).
The protein a-synuclein aggregates to form insoluble fibrils in
pathological conditions characterized by Lewy bodies, such as
Lewy body dementia and PD. When a-synuclein fused to non-
fluorescent split venus fragments is transfected into cells, oligo-
merization of two a-synuclein proteins causes these non-fluo-
rescent fragments to reconstitute a functional yellow fluorescent
protein fluorophore, which can be detected by flow cytometry.
Using this BiFC assay, significantly lower levels of a-synuclein
assemblies were observed in p38 MAPK inhibitor-treated cells
compared with control cells. The levels of co-transfected blue
fluorescent protein (BFP) were comparable between all condi-
tions, indicating that p38 MAPK inhibitor treatment does not
affect the transcription rate of BFP (Figure 5D). Importantly, the
reduction in a-synuclein protein levels was accompanied by an






Figure 5. p38 MAPK Inhibition Increases
Protein Clearance by the Proteasome
(A) Suc-LLVY-AMC conversion in lysates obtained
from MelJuSo cells after 72 hr transfection with
siRNAs targeting p38f MAPK. Lysates were
subsequently supplemented with a recombinant
p38aD176A/F372S protein or its inhibitor PD169316
or a combination of both, before AMC fluores-
cence measurements were performed. Error bars
represent SD of three independent experiments.
Statistical significance: ***p % 0.001.
(B) HA-GFP levels in MelJuSo cells treated with
5 mM of the indicated p38 MAPK inhibitors or ep-
oxomicin. All signals were normalized to intensities
obtained in DMSO-treated control (CTR) cells.
Error bars represent SD of three independent
experiments. Statistical significance: *p % 0.05,
**p % 0.01, ***p % 0.001.
(C) Immunoblot analysis showing the levels of the
indicated proteins in HeLa cells that were pre-
incubated with 5 mMPD169316, followed by a 6 hr
treatment with 1 mM dBET1. Bars represent the
quantified BRD4/CRBN ratio. Three independent
experiments were performed.
(D) a-Synuclein-yellow fluorescent protein (YFP)
levels (top), BFP levels (middle) and cell survival
(bottom) in MelJuSo cells transfected with a-syn-
uclein-split YFP and BFP and treated with 5 mM
of the indicated p38 MAPK inhibitors. All signals
were normalized to intensities obtained in DMSO-
treated control (CTR) cells. NT, non-transfected.
Error bars represent SD of three independent
experiments. Statistical significance: *p % 0.05,
**p % 0.01, ***p % 0.001 and ****p % 0.0001.
(E) In-gel fluorescence scan (top) showing repre-
sentative proteasome labeling profiles in primary
mouse neurons after a 16 hr treatment with
the indicated concentrations of PD169316 or
MG132. Immunoblot analysis (bottom) showing
the endogenous a-synuclein, b5 and GAPDH
expression levels. GAPDH levels were used as a
loading control.Finally, we tested the effect of PD169316 treatment on endoge-
nous a-synuclein levels in primary mouse neurons. To this end,
cells were treated with various concentrations of the drug, after
which both the proteasome activity and the levels of a-synuclein
were measured. As can be seen in Figure 5E, PD169316 treat-
ment increased the proteasome activity and decreased the
levels of endogenous a-synuclein. Together, these data show
that inhibition of the p38 MAPK pathway results in an increased
clearance of proteins. Furthermore, these data suggest that
inhibition of p38 MAPK is a viable strategy to therapeutically
enhance proteasome activity, which could contribute to theCell Chemicclearing of protein aggregates in neuro-
degenerative diseases such as PD.
DISCUSSION
Proteasome activation by small mole-
cules is regarded as a promising strategy
to treat or prevent neurodegenerative dis-eases characterized by the accumulation of toxic protein aggre-
gates (Dantuma and Bott, 2014; Lee et al., 2010a; Myeku et al.,
2016). However, very few in vivo small-molecule proteasome
enhancers have been described to date. One factor hampering
the identification of such compounds is the lack of suitable
screening assays. Most proteasome activity assays either work
in vitro, or depend on the introduction of tagged substrates to
monitor degradation, such as the proteasome reporter substrate
Ub-R-GFP (Dantuma et al., 2000). Although such reporter sub-
strates are well suited to monitor proteasome inhibition, their
rapid degradation at baseline proteasome activity limits theiral Biology 24, 725–736, June 22, 2017 733
use as tools to monitor enhanced activity and degradation.
Activity-based proteasome probes overcome these limitations
and are therefore powerful research tools to monitor enhance-
ment of 26S proteasome activity in both primary cells and estab-
lished cell lines and tissues (Berkers et al., 2007). In this study,
we identified over ten small molecules that increase 26S protea-
some activity in cells using such proteasome activity probes.
Our study demonstrates that activity-based probes can be
used to identify potent proteasome activators in a straightfor-
ward manner.
In addition, our data suggest that proteins in the p38 MAPK
pathway are potential targets for therapies aimed at proteasome
activation. Genetic and/or chemical inhibition of p38a, its up-
stream kinases ASK1 and MKK6, and its downstream target
MK2 all enhanced proteasome activity in cells. ASK1 and p38
MAPK have previously been shown to negatively regulate the
proteasome. Here, we identify the downstream p38MAPK target
MK2 as a novel player that modulates 26S proteasome activity,
suggesting that p38a inhibition may activate the 26S protea-
some, at least in part, via MK2. Several kinases have been
described to modulate proteasome activity through direct phos-
phorylation of the 19S RP, including ASK1 (Um et al., 2010), p38
MAPK (Lee et al., 2010b), the calcium/calmodulin-dependent
protein kinase II (CaMKII) (Djakovic et al., 2009), PKA (Asai
et al., 2009; Lokireddy et al., 2015; Zhang et al., 2007), and
DYRK2 (Guo et al., 2015). Surprisingly, extensive proteomics
studies showed that inhibition of p38 or MK2 did not result in a
statistically changed phosphorylation status of the 26S protea-
some, although we cannot exclude that the increased protea-
somal activity ismediated through (de)phosphorylation of a small
fraction of cellular proteasome, without changing global protea-
some phosphorylation levels.
Themechanism bywhich the ten other small-molecule protea-
some activators that we identified enhance proteasome activity
remains to be determined. Such studies are challenging because
of the polypharmacology exhibited by many of these com-
pounds (i.e., these compounds are likely to affect multiple intra-
cellular targets). However, many of these activators have been
described to influence Ca2+ or cAMP levels in cells. Both CaMKII
(Djakovic et al., 2009) and PKA (Asai et al., 2009; Lokireddy et al.,
2015; Zhang et al., 2007), which are activated by increased Ca2+
and cAMP levels, respectively, have been shown to phosphory-
late the proteasome, leading to its activation. Mediating cellular
entry of extracellular Ca2+ by the small-molecule bicuculline
has been shown to stimulate the degradation of proteasomal
substrates (Djakovic et al., 2009). In addition, forskolin and other
cAMP-inducing compounds promote the degradation of aggre-
gation-prone proteins that cause neurodegenerative disease (Lin
et al., 2013; Lokireddy et al., 2015). In vivo, small-molecule-
mediated PKA activation enhances 26S proteasome activity,
while reducing levels of aggregated tau (Myeku et al., 2016). It
therefore seems likely that the proteasome-enhancing proper-
ties of some of our other hits are, at least in part, mediated
through cAMPor Ca2+ signaling. This suggests that the identified
set of compounds work through multiple mechanisms in their
activation of the proteasome. We expect that elucidation of
possible other pathways involved in the regulation of 26S protea-
some activity will open up new possibilities for therapy based on
26S proteasome activity modulation.734 Cell Chemical Biology 24, 725–736, June 22, 2017For most proteasomal substrates, ubiquitination rather than
proteasomal degradation is the rate-limiting step in protein
breakdown. However, a recent study suggests that the degra-
dation of particularly short-lived proteins, including aggrega-
tion-prone proteins, is also regulated at the level of the protea-
some (Lokireddy et al., 2015). Our data indicate that p38 MAPK
inhibitors indeed do not change global levels of ubiquitinated
proteins, indicative of protein turnover, but instead induce the
degradation of only a small subset of proteins. Several p38
MAPK inhibitors promote the degradation of endogenous
a-synuclein, which (once aggregated) is the causative agent
of pathological conditions characterized by Lewy bodies,
such as PD. In addition, our data show that these inhibitors
increase the clearance of toxic a-synuclein assemblies and
rescue cell viability. The reported half-life of endogenous a-syn-
uclein is at least 24 hr (Li et al., 2004), suggesting that increased
protein degradation by activated proteasomes is not limited
to short-lived proteins only. As activated p38 MAPK has been
found to accumulate in various neurodegenerative diseases
(Kim and Choi, 2010), proteasome activation via p38 MAPK
inhibition may be especially beneficial in neurodegenerative
diseases.
SIGNIFICANCE
The 26S proteasome is responsible for the breakdown of
cellular proteins and key to protein homeostasis. Many
neurodegenerative disorders are characterized by the pres-
ence of toxic intracellular protein aggregates and reduced
26Sproteasomeactivity. Here,wedescribe the identification
of more than ten distinct small molecules that increase 26S
proteasome activity in cells. One of the identified molecules
is a knownp38MAPK inhibitor andweshow that chemical in-
hibition or depletion of p38 MAPK increase PROTACs-medi-
ated degradation of ubiquitinated proteins as well as degra-
dation of a-synuclein, causative to Parkinson’s disease.
Upon focusing on the MAPK signaling cascade, we further
identify a number of additional cellular players along this
pathway, includingMAPK-activated protein kinase 2, as pro-
teins involved in 26S proteasome activation. Our findings
indicate that enhancement of 26S proteasome activity may
be of interest as a therapeutic strategy and that such activa-
tion can be achieved easier than previously thought.
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Antibodies
Rpt6 Enzo Lifesciences Cat# BML-PW9265; RRID: AB_10555017
b5 (PSMB5) Enzo Lifesciences Cat# BML-PW8895; RRID: AB_10540901
P38 MAPK Enzo Lifesciences Cat# ADI-KAS-MA009; RRID: AB_11026937
ASK1 Abcam Cat# AB45178; RRID: AB_722915
MKK6 Enzo Lifesciences Cat# ADI-KAP-MA014; RRID: AB_10617283
MAPKAPK2 Cell Signaling Technologies Cat# 3042; RRID: AB_10694238
a-synuclein BD Transduction Laboratories Cat# 610787; RRID: AB_398108
Ubiquitin Santa Cruz Biotechnology Cat# SC-8017; RRID: AB_628423
GAPDH Life Technologies Cat# AM4300; RRID: AB_2536381
BRD4 Abcam Cat# AB128874; RRID: AB_11145462
CRBN Abcam Cat# AB98992; RRID: AB_10674459
HRP-conjugated polyclonal swine anti-rabbit DAKO Cat# P0217
HRP-conjugated polyclonal rabbit anti-mouse DAKO Cat# P0161
Chemicals, Peptides, and Recombinant Proteins
Cyclosporin A (CycA) Sigma Aldrich C30024
Dipyrimadole (Dip) Sigma Aldrich D9766
DPCPX (DP) Sigma Aldrich C101
Loperamide (Lop) Sigma Aldrich L4762
Methylbenzethonium (MB) Sigma Aldrich M7379
Mifepristone (Mif) Sigma Aldrich M8046
PD169316 Sigma Aldrich P9248
Pimozide (Pim) Sigma Aldrich P1793
Proflavine (Pro) Sigma Aldrich P2508
(±)-Verapamil (Ver) Sigma Aldrich V105
Win 62,577 (Win) Sigma Aldrich W104
SB202190 Sigma Aldrich S7067
SB203580 Sigma Aldrich S8307
Skepinone-L Stefan Laufer
(Koeberle et al., 2012)
N/A
IU1 Lee et al., 2010a I1911
dBET1 BioMol Cay18044-1
Probe 1: Me4-BodipyFLAhx3Leu3VS de Jong et al., 2012 N/A
Reduced probe 1 Berkers et al., 2005 N/A
Suc-Leu-Leu-Val-Tyr-AMC Enzo Lifesciences BML-P802
PhoSTOP Roche 4906845001




Proteasome ELISA kit Enzo Lifesciences BML-PW0575-0001
CellTiter-Blue Cell Viability Assay Promega G8080
Dynabeads mRNA DIRECT Purification kit Thermo Fischer Scientific 61011
SuperScript VILO cDNA Synthesis kit Thermo Fischer Scientific 11754250
SYBRgreen PCR Master Mix Applied Biosciences 4309155
Gel Filtration Markers Kit for Protein Molecular
Weights 6,500-66,000 Da
Sigma Aldrich MWGF70
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REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Cell Lines
Human: HEK293T cells stably expressing
HTBH-tagged Rpn11
Lan Huang (University of California,
Irvine)
N/A
Human: MelJuSo Division of Chemical Immunology,
LUMC, Leiden
N/A
Human: MCF-7 Division of Chemical Immunology,
LUMC, Leiden
N/A
Human: HEK293 Division of Chemical Immunology,
LUMC, Leiden
N/A
Human: HeLa Division of Chemical Immunology,
LUMC, Leiden
N/A




Primary mouse neurons Wiep Scheper
(de Wit et al., 2009)
N/A
Oligonucleotides
siRNA P38a (MAPK14) Sigma Aldrich SIHK1201, SIHK1202,
SIHK1203
siRNA P38b (MAPK11) Sigma Aldrich SIHK1192, SIHK1193, SIHK1194
siRNA P38g (MAPK12) Sigma Aldrich SIHK1195
SIHK1196, SIHK1197,
siRNA P38d (MAPK13) Sigma Aldrich SIHK1198, SIHK1199, SIHK1200
siRNA ASK1 Dharmacon M-003584-02
siRNA MKK6 Dharmacon M-003967-01
siRNA MK2 Dharmacon M-003516-02
siRNA PLK1 Dharmacon M-003290-01

































Thermo Fisher Scientific N/A
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant DNA
Plasmids: a-synuclein BIFC assay Tiago Outeiro
(Outeiro et al., 2008)
N/A
Plasmid: p38 MAPaD176A/F372S Avitzour et al., 2007 N/A
Plasmid: (GY)HA-GFP Jannie Borst N/A
Plasmid: Blue Fluorescent Protein (BFP) Jannie Borst N/A
Software and Algorithms
GraphPad Prism Graphpad Software Inc https://www.graphpad.com/scientific-
software/prism/
FlowJo Tree Star https://www.flowjo.com/
Max Quant (v1.5.2.8) N/A http://www.coxdocs.org/doku.php?id=
maxquant:start
Perseus (v1.5.0.0 Tyanova et al., 2016 http://www.coxdocs.org/doku.php?id=
perseus:start
ImageQuant TL 8.1 GE Healthcare Life Sciences http://www.gelifesciences.com/webapp/
wcs/stores/servlet/ProductDisplay?
categoryId=10988&catalogId=10101&
productId=25675&storeId=12251&langId=-1CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact, Huib Ovaa
(H.Ovaa@lumc.nl)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture
MelJuSo (human, melanoma), MCF-7 (human, breast adenocarcinoma), HEK293 (human embryonic kidney), and HeLa (human, cer-
vical adenocarcinoma) cells were cultured in DMEMmedium (Invitrogen Life Technologies, Carlsbad, CA, USA). THP-1 cells (human,
acute monocytic leukemia) were cultured in RPMI medium (Invitrogen Life Technologies, Carlsbad, CA, USA). All media were sup-
plemented with 10% fetal calf serum (Gibco), 100 units/mL penicillin and 100 mg/mL streptomycin. All cells were routinely tested for
Mycoplasma contaminations. Primarymouse neuronswere isolated and differentiated as previously described (deWit et al., 2009). In
brief: cerebral corticeswere dissected in Hanks Balanced Salt Solution (HBSS) and digestedwith 0.25% trypsin (Invitrogen Life Tech-
nologies, Carlsbad, CA, USA) for 20 minutes at 37C. Tissue was triturated, counted and 200.000 neurons per well were plated in a
6-well plate and cultured in Neurobasal medium supplemented with 2%B-2, 1.8%HEPES, 1% glutaMAX (Thermo Fischer Scientific,
and 100 units/mL penicillin and 100 mg/mL streptomycin (Invitrogen Life Technologies, Carlsbad, CA, USA). Treatment with com-
pounds was started after 7 days of in vitro culturing. HEK293T cells stably expressing HTBH-tagged Rpn11 were kindly provided
by Lan Huang (University of California, Irvine).
METHOD DETAILS
Chemicals
Proteasome activity probe 1 was obtained as described previously (de Jong et al., 2012). Reduced probe 1 was generated by hy-
drogenation of the vinyl sulfone warhead by Pd/C-H2 catalysis, as previously described (Berkers et al., 2005), before coupling to
the Me4-BodipyFLAhx3Leu3OH as described previously (de Jong et al., 2012). The Library of Pharmacologically Active Compounds
(LOPAC, Lot No. 067K4707) contains 1261 pharmacologically active compounds andwas purchased fromSigma-Aldrich. The Johns
Hopkins Chemical Compound Library v1.1 (JHCCL) contains 1514 approved drugs and was provided by John Hopkins University.
Unless stated otherwise, all compounds were purchased from Sigma-Aldrich at the highest available purity. dBET1 was purchased
from Biomol. The allosteric p38 MAPK inhibitor Skepinone–L was previously described (Koeberle et al., 2012) and was kindly pro-
vided by Stefan Laufer.
Antibodies
The following primary antibodies were used: Rpt6 (Enzo Lifesciences, BML-PW9265, 1:2000), b5 (PSMB5) (Enzo Lifesciences,
BML-PW8895, 1: 2500), p38 MAPK (Enzo Lifesciences, ADI-KAS-MA009, 1:1000), ASK1 (Abcam, AB45178, 1:500), MKK6 (EnzoCell Chemical Biology 24, 725–736.e1–e7, June 22, 2017 e3
Lifesciences, ADI-KAP-MA014, 1:1000), MK2 (Cell Signaling Technologies, #3042, 1:1000), a-synuclein (BD Transduction Labora-
tories, 610787, 1:1000), ubiquitin (Santa Cruz Biotechnology, SC-8017, 1:1000), BRD4 (Abcam, AB128874, 1:1000), CRBN (Abcam,
AB98992, 1:1500), and GAPDH (Life Technologies, AM4300, 1:2500). The following secondary antibodies were used: HRP-conju-
gated polyclonal swine anti-rabbit (DAKO, P0217) and HRP-conjugated polyclonal rabbit anti-mouse (DAKO, P0161).
SiRNAs
For the siRNA screen, a subset of the GEHealthcare Dharmacon RNAi smartpool library (Dharmacon, Lafayette, CO, USA) was used.
For both validation of hits and further assays, siRNAs were obtained from Sigma-Aldrich: P38a (MAPK14): SIHK1201, SIHK1202,
siHK1203. P38b (MAPK11): SIHK1192, SIHK1193, SIHK1194. P38g (MAPK12): SIHK1195, SIHK1196, SIHK1197. P38d (MAPK13):
SIHK1198, SIHK1199, SIHK1200). The following siRNAs were obtained from Dharmacon: ASK1 M-003584-02, MKK6: M-003967-
01. MK2: M-003516-02. As a control, cells were transfected with non-targeting siRNAs D-001206-13 or D-001206-14. To determine
transfection efficiency, cells were transfected with siRNA against PLK1: M-003290-01.
Plasmids
The construct encoding the constitutively active p38 MAPaD176A/F372S mutant was previously described (Avitzour et al., 2007).
Constructs encoding the a-synuclein BiFC assay (Outeiro et al., 2008) were previously described and kindly provided by Tiago
Outeiro. Constructs for (GY)HA-GFP and BFP were provided by the Division of Immunology, The Netherlands Cancer Institute,
Amsterdam, The Netherlands and previously described.
High-Throughput Screening Assays
All screens were performed on a Hamilton STAR R&D liquid handling system (Hamilton, Reno, NV, USA). For the small molecule
screens, MelJuSo cells were grown to 40% confluency in 96-well plates and incubated with 5 mM compound for 16 hours, followed
by active proteasome labeling with 250 nM probe 1 for 2 hours. For the siRNA screen, MelJuSo cells were reverse transfected
for 48 hours by seeding cells in 96-well plates preprinted with siRNAs, followed by labeling with 250 nM probe 1 for 2 hours.
After labeling, cells were washed, trypsinized and fixed with 1% formaldehyde in PBS. The fluorescence in the FL-1 channel
(530/30 nm) was measured using a BD FACScalibur (BD Biosciences, San Jose, CA, USA) equipped with an autosampler. For
both screens, samples were measured in duplicate.
Assaying Proteasome Activity Using Proteasome Activity Probe 1 (Flow Cytometry)
For small molecule assays, the adherent cell lines MelJuSo, HeLa, MCF-7, N2A and the suspension cell line THP-1 were incubated
with 5 mM compound for 16 hours, followed by labeling with 250 nM probe 1 or control probe 1 for 2 hours. Adherent cells were
approximately 40% confluent at the start of the incubation. For THP-1 cells approximately 500.000 cells were used. After labeling,
cells were washed, trypsinized and fixed with 1% formaldehyde in PBS. The fluorescence in the FL-1 channel (530/30 nm) was
measured using a BD FACScalibur (BD Biosciences, San Jose, CA, USA) equipped with an autosampler. Cells treated with
DMSO only or 750 nMMG132 were used as untreated or negative controls, respectively. Three independent experiments measured
in triplicate were performed. Fluorescence data were normalized by setting the DMSO only-treated samples as 1. For siRNA assays,
MelJuSo cells at an approximate confluency of 30%were transfected for 48 hours with 25 nM siRNA listed above using DharmaFECT
1 as transfection reagent, followed by labeling with 250 nM probe 1 for 2 hours. After labeling, cells were washed, trypsinized and
fixed with 1% formaldehyde in PBS. The fluorescence in the FL-1channel (530/30 nm) was measured using a BD FACScalibur
(BD Biosciences, San Jose, CA, USA) equipped with an autosampler. Cells transfected with non-targeting siRNA were used as un-
treated control and transfection efficiency was verified by using cells transfected with siRNA against PLK-1. Fluorescence data were
normalized by setting the non-targeting siRNA-treated samples as 1. Three independent experiments measured in triplicate were
performed.
Assaying Proteasome Activity Using Proteasome Activity Probe 1 (SDS-PAGE)
Cells were treated with compounds as described above. After labeling, cells were harvested and resuspended in HR buffer (50 mM
Tris, 5 mMMgCl2, 250mM sucrose, 1mMDTT and 2mMATP, pH=7.4). Cell lysis was achieved by sonication (Bioruptor, Diagenode,
high intensity for 5minuteswith anON/OFF cycle of 30 seconds) at 4C. After a centrifugation step (21.100g for 15minutes) to remove
cell debris, protein concentration of the supernatant was determined by a NanoDrop spectrophotometer (Thermo Fisher Scientific)
by measuring the absorbance at 280 nm. Equal amounts of protein were denatured by boiling in LDS (lithium dodecyl sulfate) sample
buffer (Invitrogen Life Technologies, Carlsbad, CA, USA) containing 2.5% b-mercaptoethanol. Polypeptides were resolved by 12%
SDS-PAGE using the NuPAGE system and MOPS running buffer (Invitrogen Life Technologies, Carlsbad, CA, USA). Wet gel slabs
were imaged for 60 seconds, with a resolution of 100 mm, using the ProXPRESS 2D Proteomic imaging system (Perkin-Elmer),
with appropriate filter settings (l(ex/em) =480/530 nm). To verify equal protein loading, gels were stained with Coomassie brilliant
blue (CBB). For Western Blot analysis, proteins were transferred onto PVDF membrane using the Trans-Blot Semi-Dry Transfer
Cell (Bio-Rad). Proteins were transferred at 12 V for 50 minutes. Membranes were blocked with 5% BSA solution and subsequently
incubated with primary antibody overnight at 4C. After washing with PBS-Tween 20 (0.2%) membranes were incubated with
secondary antibody and signals visualized by using a Bio-Rad ChemiDoc Imaging System. Immunoblotting with an antibody against
GADPH was used to verify equal protein loading. Three independent experiments were performed.e4 Cell Chemical Biology 24, 725–736.e1–e7, June 22, 2017
Assaying Proteasome Activity with Fluorogenic Substrates
An equal amount of MelJuSo wild-type cells were seeded in a 96-wells plate. After overnight culturing cells were approximately 40%
confluent and were treated with 5 mM compound for 16 hours unless indicated otherwise. Cells were then washed with PBS and
100 mL of assay buffer (20 mMTris, 5 mMMgCl2, 1mMDTT, 1mMATP, pH=7.4) containing 100 mMsuc-LLVY-AMC (Enzo Lifescien-
ces) was added to the cells. Fluorescence was measured every 5 minutes for 50 minutes at 37C using a Fluostar Optima 96-well
plate reader (BMG Labtechnologies; lex / em) = 355 / 450 nm), and the increase in fluorescence per minute was used to calculate
the activity of each sample compared to DMSO only-treated cell (100%) and cells treated with 1 mM epoxomicin (0%). Three inde-
pendent experimentsmeasured in triplicate were performed. Data were analyzed and statistical analyses performed usingGraphPad
Prism software (GraphPad, La Jolla, CA, USA). To exclude the possibility that the observed results were the consequence of differ-
ences in cell number, cell density was subsequently measured. For assaying proteasome activity with fluorescent substrates after
siRNA transfection, the following approach was used: MelJuSo cells transfected for 48 hours with either non-targeting siRNA or
siRNA targeting p38MAPKa, ASK1, MKK6 or MK2 were washed, trypsinized and counted. For each condition equal amounts of cells
were seeded in a 96-wells plate and cultured for additional 6 hours. Cells were washedwith PBS and suc-LLVY-AMC conversion was
determined as described above. The activity of samples treated with non-targeting siRNA was set as a 100%. After the fluorescent
measurement cells were harvested and a Western blot analysis performed to verify knockdown of the respective proteins. To assay
the activity of isolated 26S proteasomes (described below) from HEK293T cells stably expressing HTBH-tagged Rpn11, 1 mg of iso-
lated 26S proteins was transferred to a 96-wells plate after which 100 mL of assay buffer was added and the fluorescence measured
as described above.
Assaying Proteasome Activity with Fluorescent Reporter Proteins
MelJuSo cells were plated 24 hours, growing to 30–40% confluency prior to transfection. Transfection was performed using
Superfect reagent (Qiagen, Chatsworth, CA, USA) according to the manufacturer’s instructions and as previously described (31).
Cells were transfected with 0.02 mg DNA for (GY)HA-GFP or 0.02 mg of each of the plasmid for a-synuclein. After 48 hours, the com-
pounds were added at the indicated concentrations for 16 hours, after which the fluorescence was measured in the FL-1 channel
(530/30 nm using a BD LSRFortessa (BD Biosciences, San Jose, CA, USA). Three independent experiments measured in triplicate
were performed.
PROTAC-Induced Proteolytic Targeting of BRD4
HeLa cells were plated 24 hours, growing to 30-40% confluency prior to treatment with either DMSO or 5 mMPD169316 for 16 hours.
PROTAC-induced proteolytic targeting of BRD4 (Winter et al., 2015) was induced by treating cells with 1 mM of dBET1 for 6 hours,
followed by labeling with 250 nMprobe 1 for 2 hours. Fluorescence scanning and immunoblotting was performed as described above
to determine the levels of proteasome activity, BRD4 and Cereblon (CRBN). Immunoblotting with an antibody against GADPH was
used to verify equal protein loading. Three independent experiments were performed.
CellTiter-Blue Cell Viability Assay
Cells (20% confluent) were incubated with 5 mM compound for 72 hours, followed by incubation with the Cell-Titer-Blue assay re-
agent (Promega) according to the manufacturer’s instruction. The increase in fluorescence (544 nm excitation and 590 nm emission)
was measured after 8 hours using an EnVision plate reader (Perkin-Elmer). All results were expressed as a percentage relative to a
DMSO-treated control. Three independent experiments measured in triplicate were performed.
20S Proteasome ELISA
The levels of 20S proteasome in cells after treatment with different compounds were determined using a commercially available Pro-
teasome ELISA kit according to the manufacturer’s instruction (Enzo LifeSciences). Fluorescence was detected using a VictorX2
Multilabel Plate reader and data were normalized using DMSO-only treated cells as a control. Three independent experiments
measured in triplicate were performed.
Proteasome Isolation
HTBH-Rpn11-HEK293T cells were treated with 5 mM of the indicated compounds for 16 hours after which cells were washed and
collected by scraping in lysis buffer (100 mM NaCl, 50 mM sodium phosphate, 10% glycerol, 5 mM ATP, 1 mM DTT, 5 mM
MgCl2, 13 protease inhibitor (Roche), 13 phosphatase inhibitor (Roche), and 0.5% NP-40 (pH 7.5)). After a centrifugation step
(21.100 g for 15 minutes) HTBH-tagged Rpn11-containing 26S proteasomes were isolated from the lysate by overnight incubation
at 4C with streptavidin beads. After 3 washes with wash buffer (50 mM Tris-HCl (pH 7.5)), 10% glycerol, 1 mM ATP), 26S protea-
somes were cleaved from the beads by treatment with 1% TEV enzyme (protein expressed and purified in-house by the NKI protein
facility) for 1 hour at 30C in wash buffer. Protein concentration was determined using NanoDrop. For proteomic analysis, protea-
some isolation was performed four separate times for each condition.
Real-Time PCR
Quantitative RT-PCRwas performed to determine themRNA expression levels of the proteasome subunits PSMB5 (b5), PSMB6 (b1),
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previously described. mRNA was isolated using the Dynabeads mRNA DIRECT Purification kit (Thermo Fisher Scientific) according
to the manufacturer’s instructions after which cDNA was generated using SuperScript VILO cDNA Synthesis kit (Thermo Fisher
Scientific). RT-PCR analysis was performed using SYBRgreen PCR Master Mix (Applied Biosciences) on a Chromo4 DNA Engine
detection system (Bio-Rad) according to the manufacturer’s instructions. Samples were amplified during 40 cycles of 15 seconds
at 95C and 60 seconds at 60C. Relative mRNA expression levels of the target genes in each sample were calculated using the
comparative cycle time (Ct) method (39) and normalized to either DMSO only-treated controls or non-targeting siRNA control.
Primers and concentrations used for the quantitative real-time PCR were as follows:
PSMB5 forward (50 nM): 5’-CTTCAAGTTCCGCCATGGA-3’; PSMB5 reverse (300 nM): 5’-CCGTCTGGGAGGCAATGTAA-3’;
PSMB6 forward (50 nM): 5’-AGGCATGACCAAGGA-AGAGTGT-3’; PSMB6 reverse (300 nM): 5’-GAGCCATCCCGCTCCAT-3’;
PSMB7 forward (50 nM): 5’-TCGGTGTATGCTCCACCAGTT-3’; PSMB7 reverse (300 nM): 5’-GCAAAATCGGCTT-CCAAGAC-3’;
GUS forward (300 nM): 5’-GAAAATATGTGGTTG GAGAGCTCATT-3’; GUS reverse (300 nM): 5’-CCGAGTGAAGATCCCCTTTTTA-3’;
p38a MAPK forward (100 nM): 5’-AAGACTCGTTGGAACCCCAG-3’; p38a MAPK reverse (300 nM): 5’-TCCAGTAGGTCGAC-AGC
CAG-3’; p38b MAPK forward (100 nM): 5’-AGCCCAGTGTCCCTCCTAA-3’; p38b MAPK reverse (300 nM): 5’-CCACAGGCAACCA
CAAATCT-3’; p38g MAPK forward (100 nM): 5’-AGCCCTCAGGCTGTGAATCT-3’; p38g MAPK reverse (300 nM): 5’-CATATTTCTG
GGCCT-TGGGT-3’; p38d MAPK forward (100 nM): 5’-GCTCACCCCTTCTTTGAACC-3’; p38d MAPK reverse (300 nM): 5’-TTCGTC
CACGCTGAGTTTCT-3’.
Sample Preparation for SEC Proteomics Analysis
MelJuSo cells were lysed by brief sonication in the SEC-running buffer (150 mM NH4Ac, pH 7.2) complemented with PhosStop and
complete mini EDTA-free inhibitor cocktail (Roche). Lysates were clarified by centrifugation at 20-000g for 10 minutes at 4C. Total
protein concentration was determined with a Bradford assay and equal protein amounts of all treatment conditions were used for
further sample preparation steps. The cell lysates were then concentrated through a Vivaspin 100 kDa molecular weight cutoff filter
(Sartorius Stedim Biotech GmbH, Germany).
Concentrated samples were subsequently fractionated using an Åkta p900 LC system (Amersham Biosciences), equipped with a
BioSep SEC s4000 column (600x7.8mm, 500Å, Phenomenex) with a flow of 450 ml/min. The Before the lysates amix ofmolecular with
warkers was run over the column (Gel Filtration Markers Kit for Protein Molecular Weigths 6,500-66,000 Da., Sigma-Aldrich). The
eluted lysate sample was collected in fractions of 260 ml. 4M urea lysis buffer was added and fractions containing the proteasome
were heated at 99C for 5 minutes. Thereafter samples were reduced (4 mM DTT) and alkylated (8 mM iodoacetamide) and proteins
were first digested using LysC (1: 75 enzyme/protein ratio, Wako) for 4 hours at 37C and 2 times diluted with ammonium bicarbon-
ate. Next, trypsin (1:50, Sigma-Aldrich) was added for further protein digestion, and the samples were incubated overnight at 37C.
The fully digested samples were acidified to 1% formic acid (Merck). Sample cleanup was performed using OASIS sample cleanup
cartridges (Waters). Samples were then analyzed by LC-MS/MS.
Proteasome Enriched (Phospho)Proteomics Analysis
After proteasome affinity purification, samples were further diluted in 50 mM ammonium bicarbonate (pH 8.5) complemented with
PhosStop and complete mini EDTA-free inhibitor cocktail (Roche) and digested as described above. Samples were desalted with
Sep-Pak C18 cartridges (Waters), split in two replicates and dried down. One half of the samples was stored at -80C before LC-
MS/MS analysis and the other half of the sample was used for phosphorylated peptide enrichment. Phosphorylated peptides
were enriched using Fe(III)-NTA cartridges (Agilent technologies) in an automated fashion using the AssayMAPBRAVOPlatform (Agi-
lent technologies). The cartridges were primedwith 0.1% trifluoroacetic acid in acetonile and equilibrated with 80%acetonitrile/0.1%
TFA (loading buffer). The samples were then dissolved in loading buffer and loaded onto the cartridges. The cartridges were washed
with loading buffer and phosphorylated peptides were eluted with 1%ammonia directly into 10%FA, dried down and stored at -80C
untill LC-MS/MS analysis (Zhou et al., 2013).
Liquid Chromatography and Mass Spectrometry
All samples were reconstituted in 10% FA. In total. 40% of the eluted phosphopeptides per sample were used for further analysis. All
samples were analyzed using aQ-Exactive Plus Orbitrap instrument (Thermo Fisher Scientific, Bremen) connected to an Agilent 1290
HPLC system. The trap column was made of reversed phase C18material (Dr. Maisch Reprosil, 3 mm,2 cm x 100 mm) and the analyt-
ical column was a 50 cm, 75 mm inner diameter capillary packed with Poroshell C18 material (Agilent, 120EC-C18, 2.7 mm). Both the
trap column and analytical column were packed in-house. Solvent A consisted of 0.1% formic acid (Merck) in deionized water
(Milli-Q, Millipore) and solvent B consisted of 0.1% formic acid in 80% acetonitrile (Biosolve). Peptides were first trapped at 50 ml/min
with solvent A and then eluted with solvent B in a 120 min gradient at 100 nl/min: 0–10 min, 100% solvent A; 10.1–105 min, 13–40%
solvent B; 105–108 min, 40-100 % solvent B; 108–109 min, 100 % solvent B; 109-110 min, 0–100% solvent A; 110–120 min, 100 %
solvent A. The Orbitrap was operated in a data-dependent manner, with the following settings: ESI voltage, 1700 V; Inlet Capillary
Temperature 320C; full-scan automatic gain control (AGC) target, 3 3 106 ions at 35 000 resolution; scan range, 350–1500 m/z;
Orbitrap full-scan maximum injection time, 250 ms; MS2 scan AGC target, 5 3 104 ions at 17 500 resolution; maximum injection,
120 ms; normalized collision energy, 25; dynamic exclusion time, 30; isolation window 1.5 m/z; 10 MS2 scans per full scan.e6 Cell Chemical Biology 24, 725–736.e1–e7, June 22, 2017
Data Processing
RAW data files were processed with Max Quant (v1.5.2.8) and MS2 spectra were searched with the Andromeda search engine
against the human proteome in UniProt (20.197 entries, downloaded on 16-07-18 from the uniprot.org website). Enzyme specificity
was set to Trypsin/P and two missed cleavages were allowed. Both methionine oxidation and phospho (STY) were set as variable
modifications and cysteine carbamidomethylation was set as fixed modification. Minimal peptide length was 7 amino acids. Mass
tolerance was set to 20 ppm for peptide masses and 0,6 Da for fragmentation masses. FDR threshold was set to 1 % for identifica-
tions. Minimal ratio count was set to 2 for protein quantification and the functions ‘‘LFQ’’, ‘‘match between runs’’ and ‘‘requantify’’
were enabled. Perseus (v1.5.0.0) was used for data processing (Tyanova et al., 2016). A minimal localization probability of 0.75
was used for the phosphosite localization. To obtain multiple testing adjusted p-values, we performed Benjamini-Hochberg (Benja-
mini and Hochberg, 1995) in R v3.2.5.
QUANTIFICATION AND STATISTICAL ANALYSIS
Fluorescent signal of in-gel fluorescent scans was quantified using ImageQuant TL 8.1(GEHealthcare Life Sciences. Suc-LLVY-AMC
conversion data are presented asmean ± SD of three independent experiments. The conversion rates in DMSO-treated control (CTR)
cells and epoxomicin-treated cells (Epox) were set to 1 and 0, respectively. Intracellular fluorescence intensities determined by flow
cytometry are presented as mean ± SD of three independent experiments. Cell viability experiments are presented as mean ± SD
of three independent experiments. Statistical significance: ns = not significant, * = P % 0.05, ** = P % 0.01, *** = P % 0.001, and
**** P % 0.0001 as determined by t-test.Cell Chemical Biology 24, 725–736.e1–e7, June 22, 2017 e7
